Category: Tuberculosis
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
Directly Observed Therapy
vs Self-administered treatment (S |
Tuberculosis
Tuberculosis patients |
Among tuberculosis patients in Taipei, Taiwan (2006–2008), those receiving directly observed treatme
aOR 0.60 |
↑ |
3289585
Duration of TB treat |
| 📊 |
Directly Observed Therapy
vs Self-administered treatment (S |
Tuberculosis
Tuberculosis patients |
In univariate analysis, DOT was associated with increased all-cause mortality among TB patients, lik
Not specified numerically |
↓ |
3289585
Duration of TB treat |
| 📊 |
Directly Observed Therapy
vs Earlier years with lower DOT c |
Tuberculosis
Tuberculosis patients |
From 2006 to 2008, as DOT coverage increased among TB patients in Taipei, all-cause mortality decrea
Mortality decreased from 18.0% (2006) to |
↑ |
3289585
3 years |
| 📊 |
Directly Observed Therapy
vs Self-administered treatment (S |
Tuberculosis
Tuberculosis patients |
The protective effect of DOT on all-cause mortality among TB patients was influenced by AFB smear st
aOR 0.60 (adjusted for AFB status); inte |
↑ |
3289585
Duration of TB treat |
| 📊 |
Directly Observed Therapy
vs Earlier years with lower DOT c |
Tuberculosis
Tuberculosis patients |
By 2008, 57.5% of TB patients in Taipei were receiving DOT, and all-cause mortality had decreased to
DOT coverage increased from 32.9% (2006) |
↑ |
3289585
3 years |
| 📊 |
Directly Observed Therapy
vs Self-administered treatment (S |
Tuberculosis
Tuberculosis patients |
After adjusting for sociodemographic factors, clinical findings, and comorbidities, DOT was associat
aOR 0.60 (adjusted for sociodemographic |
↑ |
3289585
Duration of TB treat |
| 📊 |
Directly Observed Therapy
vs Self-administered treatment (S |
Tuberculosis
Tuberculosis patients |
After adjusting for comorbidities, DOT was associated with 40% lower odds of all-cause mortality com
aOR 0.60 (adjusted for comorbidities) |
↑ |
3289585
Duration of TB treat |
Directly observed therapy (DOT) was associated with a 40% lower odds of all-cause mortality among tuberculosis patients compared to self-administered therapy, after adjusting for sociodemographic and clinical factors (aOR 0.60). (3289585) As DOT coverage increased from 32.9% to 57.5% among TB patients in Taipei between 2006 and 2008, all-cause mortality decreased from 18.0% to 16.2%. (3289585) The protective effect of DOT on mortality was more apparent in patients with positive AFB smear status, with an adjusted odds ratio of 0.60 and a borderline significant interaction (P=0.071). (3289585) After adjusting for comorbidities, DOT remained associated with a 40% reduction in all-cause mortality compared to self-administered therapy (aOR 0.60). (3289585) Univariate analysis suggested DOT was associated with increased all-cause mortality, likely due to selection bias where sicker patients were more likely to receive DOT. (3289585)